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Mesenchymal stem cells in tissue repairing and 
regeneration: Progress and future
Introduction 
Knowledge of  the presence of  mesenchymal progenitor 
cells within bone marrow can be traced back to the late 
nineteenth century to the work of  Goujon[1] and Biakow[2] 
on the heterotopic transplantation of  rabbit marrow. The 
definitive evidence that bone marrow includes some non-
hematopoietic, plastic-adherent precursor cells was originally 
provided by Friedenstein and his colleagues, who grew whole 
bone marrow cells in a medium supplemented with 10% 
selected fetal bovine serum to demonstrate the ability of  a 
rare population of  plastic-adherent cells (approximately 1 in 
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10,000 nucleated cells in the bone marrow) to form spindle-
like and round-shaped colonies. Friedenstein defined these 
fibroblast precursors as fibroblast colony-forming units 
(CFU-F), analogous to hematopoietic colony-forming 
units.[3] As other groups subsequently extended these initial 
observations, the CFU-F progenitors were accepted to 
be multipotent and able to differentiate into adipocytes, 
osteoblasts, and chondrocytes. Arnold Caplan first used 
the term mesenchymal stem cells[4] based on the notion of  
a stromal stem cell proposed by Maureen Owen.[5] To date, 
mesenchymal stem cells (MSCs) have been reported to have 
been isolated from several different connective tissues, such 
as adipose tissue, muscle, placenta, umbilical cord matrix, 
blood, liver, and dental pulp. Bone marrow, however, is still 
one of  the major sources for MSCs used in preclinical and 
clinical research.[6]
Since the initial use of  the term “MSC,” the stem cell 
identity of  MSCs has been the subject of  considerable 
debate. In 2000, a workshop at the Annual Meeting of  
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the International Society for Cellular Therapy (ISCT) 
concluded that there was a lack of  solid data in support of  
the ‘stemness’ of  unfractionated plastic-adherent cells from 
bone marrow.[7] In 2005, the ISCT proposed “multipotent 
mesenchymal stromal cells” as a replacement term for 
“mesenchymal stem cells,” although the two terms shared 
the abbreviation “MSC”.[8] The ISCT then suggested 
minimal criteria for the definition of  human MSCs: 
(1) MSCs must be plastic-adherent when maintained in 
standard culture conditions; (2) MSCs must express CD105, 
CD73, and CD90, while lacking expression of CD45, CD34, 
CD14 or CD11b, CD79a or CD19, and HLA-DR surface 
molecules; and (3) MSCs must be capable of  differentiating 
into osteoblasts, adipocytes, and chondroblasts in vitro.[9] 
All criteria must be satisfied, as no single characteristic is 
sufficient for identifying MSCs. The bone marrow-derived 
plastic-adherent cell population also contains endothelial 
cells, fibroblasts, and macrophages. Contamination by 
hematopoietic and endothelial cells can be ruled out by the 
combination of  cell surface markers. However, no specific 
markers currently exist that can reliably discriminate 
between passaged MSCs and fibroblasts. Furthermore, 
colony-forming capacity and differentiation potential are 
important specific properties that distinguish MSCs from 
fibroblasts.[10] Recently, it was reported that the level of  
expression of  CD166 was significantly higher in MSCs 
than in fibroblasts, while the expression level of  CD9 was 
significantly lower. CD146 was found to be exclusively 
expressed in MSCs; however, CD146 was downregulated 
and CD9 was upregulated with the passage of  MSCs. The 
expression levels of  all other markers were unchanged.[11]
Initially heralded as stem cells, MSCs were first evaluated 
for regenerative applications. MSCs have since been 
shown to directly influence the immune system[12] and to 
promote the neovascularization of  ischemic tissues.[13,14] 
These observations have prompted MSC transplantation 
as a treatment for various diseases. In this review, we 
summarize the important studies of  MSCs that describe 
the potential use of  these cells as a therapeutic agent for 
regenerative medicine, immune disorders, cancer, and gene 
therapy. Furthermore, we discuss the mechanisms involved 
in MSC therapy as well as clinical-grade cell manufacturing 
of  MSCs. 
Identification of mesenchymal stem cells
Although MSCs have been isolated from many postnatal 
organs and tissues, bone marrow stroma is still the most 
recurrent tissue source utilized in cultivating MSCs. 
Most MSC populations have been isolated using methods 
similar to those originally used by Friedenstein and his 
colleagues.[15] In general, low-density mononuclear cells 
from normal human donors are plated in a basal medium 
supplemented with selected batches of  fetal bovine 
serum, and the cells that readily adhere to plastic culture 
dishes and form large CFU-F clones are considered to be 
primary MSCs. Although endothelial cells, macrophages, 
lymphocytes, and differentiated smooth muscle cells 
can also adhere to plastic and contaminate the MSC 
culture, these cells are not successfully passaged and 
expanded in the specialized culture medium. After 
a few passages, the MSC cultures display a rather 
homogenous population of  fibroblast-like cells. These 
cells lack CD11 and CD14 (monocyte and macrophage 
markers), CD34 (primitive HSCs and endothelial cells), 
CD45 (pan-leukocytes), CD19 (B cells), CD3 (T-cell 
receptor), CD31 (endothelial cells), and HLA-DR, 
but they show expression of  CD29, CD144, CD166, 
CD105, and CD90. All of  these markers are used 
retrospectively to identify MSCs via the elimination 
of  endothelial and hematopoietic cell contaminants.[16] 
Immunofluorescence and immunohistochemical staining 
have also demonstrated that bone marrow (BM)-MSCs 
were positive for myofibroblastic markers, such as 
-SMA, vimentin, fibronectin, and N-cadherin, but 
negative for epithelial markers, such as CK18 and 
E-cadherin.
Until now, the best marker for prospectively identifying 
MSCs has remained unclear. A few papers have reported 
the isolation of  MSCs using surface markers such as 
Nestin,[17] stage specific embryonic antigen-1 (SSEA-1),[18] 
SSEA-4,[19] and Stro-1. Nestin-positive cells in human bone 
marrow represent true mesenchymal stem cells in that they 
show a close physical association with hematopoietic stem 
cells (HSCs) and can express a high level of  core HSC 
maintenance genes. However, whether this putative MSC 
marker can be utilized to isolate MSCs from other tissues 
remains to be determined. 
In addition to the morphologic and phenotypic 
characteristics of  MSCs, one of  the hallmarks for the 
identification of  MSCs is their multipotent ability to 
differentiate into various lineages, including adipose, bone, 
cartilage, and myogenic cells.[9] To induce adipogenic 
differentiation, MSCs were cultured in regular medium 
supplemented with dexamethasone, insulin, isobutyl 
methyl xanthine, and indomethacin. Adipogenic 
differentiation was verified by the accumulation of  lipid 
vacuoles, which were detected by Oil Red O staining. 
These differentiated cells also expressed adipogenic 
lineage-specific genes, such as peroxisome proliferation-
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activated receptor 2 (PPAR2), lipoprotein lipase (LPL), 
fatty acid-binding protein (aP2), adipsin, and leptin. To 
promote the differentiation of  MSCs into osteoblasts, 
confluent monolayers of  MSCs were incubated with 
ascorbic acid, -glycerol phosphate, and dexamethasone; 
in addition, bone morphogenic proteins (BMPs), 
particularly BMP-2 and BMP-6, were sometimes added to 
the induction system and strongly promoted osteogenesis 
in MSCs. Early osteogenic differentiation was evaluated 
by alkaline phosphatase staining, and late osteogenic 
differentiation was assessed by von Kossa staining for 
calcium mineralization detection. Meanwhile, specific 
gene expression of  osteocalcin (OCN), osteopontin (OPN), 
Runx2, and alkaline phosphatase (ALP) was determined 
to confirm osteoblastic differentiation. For chondrogenic 
differentiation, MSCs were usually centrifuged gently 
to form a micromass and then cultured in serum-free 
High Glucose Dulbecco’s Modified Eagle Media (HG-
DMEM) and supplemented with dexamethasone, Insulin- 
Transferrin- Selenium (ITS), ascorbic acid, sodium 
pyruvate, proline, and transforming growth factor-3. 
The development and accumulation of  cartilage matrix 
was shown by staining proteoglycans with toluidine 
blue, alcian blue, and safranin O. Differentiated MSCs 
also express chondrogenic-specific genes, such as type II 
collagen and aggrecan.[20] Further studies have shown that 
MSCs can also differentiate into bone marrow stromal 
cells, tendon-ligament fibroblasts, myocytes, endothelial 
cells, neurons, and tenocytes.[21]
Mesenchymal stem cells for regenerative 
medicine
It is known that MSCs can be used for the treatment of  
injured myocardium, skin, pancreas, and bone. Although 
the exact mechanisms of  action have not been fully 
elucidated, studies show that MSCs can act on several 
levels of  endogenous repair to bring about treatment 
of  disease. MSCs have been shown to directly promote 
tissue repair.[22,23] When administered to treat animals 
undergoing acute renal failure, MSCs promoted the 
proliferation of  renal-tubule epithelial cells.[24] MSCs 
can directly protect and repair damaged -islets from 
Figure 1: Characteristics of MSCs from adult healthy bone marrow (Modifi ed from Yan et al.[20]) (a) Representative morphology of MSCs derived 
from healthy adult bone marrow. (b) Flow cytometry analysis of BM-MSC showed that BM-MSC is positive for mesenchymal markers and negative 
for endothelial and hematopoietic markers. (c) After specifi c adipogenic induction, BM-MSCs showed many lipid vacuoles that were verifi ed by Oil 
Red O staining. (d) After being cultured in an osteogenic medium for 4 weeks, BM-MSCs showed early osteogenic differentiation capacity through 
ALP staining. Late calcium deposits in the extracellular matrix were verifi ed by von Kossa staining. (e) BM-MSCs demonstrated chondrogenic 
differentiation potential as shown by toluidine blue staining, Alcian blue staining, Safranin O staining and H&E staining (cited from Fiorina et al). 
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autoimmune attacks [Figure 1].[25] MSCs can differentiate 
into osteoblasts and chondrocytes. The osteoblastic 
potential of  MSCs may be exploited for treating long 
bone defect.[26] Although MSCs are effective for long 
bone reconstruction, MSCs are not effective for jaw 
reconstruction[27] because MSCs from the bone marrow 
cannot differentiate into osteoblasts when implanted in 
the jaw.[28] These data emphasize the importance of  the 
origin of  MSCs used for tissue repair.
Evidence for the actual and potential clinical applications 
of  MSCs for cardiovascular diseases comes from the 
findings that MSCs can spontaneously differentiate into 
beating cardiomyocytes that respond to physiological 
and pharmacological stimuli.[29] Many clinical trials have 
been performed that primarily focused on treating heart 
damage.[30] The treatment was found to be safe and resulted 
in improved cardiac performance of  the MSC-injected 
group and is thus very encouraging. 
It was shown that MSCs could improve the healing of  skin 
defects in humans. Recent data suggest that autologous and 
allogeneic MSCs appear to be equally effective for wound 
repair.[31,32] A shortcoming of  using MSCs for wound repair 
is the heterogeneity of  methods used for MSC culture as 
well as the lack of  functional characterization of  MSCs. 
Finally, MSCs have also been proposed for the treatment 
of  spinal cord injury,[33] stroke,[34] amyotrophic lateral 
sclerosis[35] and neurometabolic diseases.[36] 
Mesenchymal stem cells for treating 
immune disorders
MSCs demonstrate a profound inhibitory effect on T, B, 
dendritic cells and natural killer cell proliferation in vitro 
and in vivo. These results suggested that MSCs could be 
used to cure immune disorders. Bartholomew et al.,[37] 
first demonstrated that the administration of  MSCs 
could prolong skin graft survival. Currently, more than 
12 preclinical animal models have been developed to 
demonstrate the capabilities of  MSCs in modulating the 
immune system.[38] Le Blanc and colleagues have shown that 
MSCs can successfully cure severe, treatment-resistant graft-
versus-host disease (GvHD).[39,40] However, the use of  MSCs 
to prevent the rejection of  allogeneic organ transplantation 
is still limited to animal models, and the obtained results 
have been conflicting.[41] 
MSCs have also been proposed as a treatment for 
autoimmune diseases.[42] The intravenous injection of  
MSCs into diabetic nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice resulted in an 
increased number of  pancreatic islets and insulin-producing 
 cells.[43] Indeed, MSCs have been used for the treatment 
of  rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE) and multiple sclerosis (MS).
Studies have been performed to investigate the effect of  
MSCs on experimental autoimmune encephalomyelitis 
(EAE).[44] More recently, it was shown that the intravenous 
infusion of  MSCs also suppresses pathogenic B cell 
responses in vivo.[45] A decrease in neuronal loss was 
observed in EAE mice treated with MSCs, suggesting a 
protective effect on damaged tissues.[45]
MSCs can also provide support for the growth and 
differentiation of  haemopoietic progenitor cells and can 
promote the engraftment of  haemopoietic stem cells. It 
was shown that the proliferation of  activated lymphocytes 
were suppressed by MSCs in a non-human leukocyte 
antigen (HLA) restricted manner.[46] A clinical trial has 
been in progress that investigates the use of  MSCs in 
treating hematologic malignancy by co-transplanting 
MSCs and HSCs from HLA-identical siblings of  the study 
participants.[47] It was exciting that, in 2008, the US Food 
and Drug Administration (FDA) gave the green light 
to clinical trials for the application of  MSCs in MS and 
articular cartilage repair.
Mesenchymal stem cells for anticancer 
treatment 
human MSCs (hMSCs) engraft and remain detectable at 
the injured sites and can co-localize with the sites of  tumor 
development.[48] Thus, MSCs could be used as drug carriers 
for the treatment of  tumors. The homing potential of  
hMSCs was demonstrated in vitro by hMSC coculture with 
glioma cells or glioma-conditioned medium that increased 
hMSC invasiveness.[49] In vivo, hMSCs could efficiently 
home to brain tumors and human glioma xenografts.[50] 
Unfortunately, culture-expanded hMSCs lose CXCR4, 
which is a key receptor responsible for hematopoietic stem 
cell homing.[51] However, in vitro 3-D culturing of  hMSCs 
as spheroids increases stromal cell-derived factor 1 (SDF1) 
signaling, restoring the functional expression of  CXCR4 
that is crucial for the therapeutic application of  MSCs.[51] 
Many cytokines and growth factors also enhance hMSC 
migration,[50,52] and many of  those factors are secreted by 
tumor cells.[50] The migration of  MSCs toward tumor cells 
is accompanied by the expression of  various proteins.[52] 
This is similar to the in vivo myocardial injury recruitment 
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of  MSCs by the establishment of  an SDF1 gradient toward 
the heart.[53] 
It  was shown that in vitro  hMSC chondrogenic 
predifferentiation increases engraftment during in vivo 
cartilage repair.[54] Moreover, both the sustained delivery of  
growth factors to injected MSCs and the cotransplantation 
of  MSCs with healthy tissue parts[55] can improve the MSC 
engraftment.[54] 
Because of  the ability of  hMSCs to migrate to distant 
tumors, strategies of  using them in anticancer therapies 
are being developed. The limited lifespan of  hMSCs can be 
prolonged by gene modification.[56] The tumor suppressors 
are not downregulated in transduced MSCs, suggesting 
that the growth of  these cells is still normal.[56] It will be 
very exciting to see if  genetically modified MSCs can 
directly act as a drug vehicle that causes the complete, 
irreversible elimination of  tumors. The treatment of  
human colon cancer with MSCs expressing a suicidal 
tyrosine kinase gene resulted in tumor elimination.[57] 
Therefore, gene-modified MSCs with homing potential 
could be used to treat tumors that cannot be cured with 
conventional drugs. 
Mesenchymal stem cells for gene therapy 
Genetic engineering of  cells has become a mainstay in 
cell and molecular biology, and MSCs offer a unique 
opportunity to establish transplantation schemes to correct 
genetic diseases. These cells may be easily obtained, 
manipulated genetically, and expanded in number before 
reintroduction. This eliminates the limitations and risks 
associated with the delivery of  genetic repair material 
directly to the patient via pathogen-associated vectors. 
Furthermore, there is far less concern of  inappropriate 
differentiation than in human embryonic stem cells. 
If  a short-lived effect, such as bone regeneration, is the goal, 
transient transduction would be the desired outcome and 
utilized methods might include electroporation, chemical 
methods, plasmids, and viral constructs such as adenovirus. 
For the treatment of  recessive diseases, permanent 
transduction is required, which has depended on the use 
of  adeno-associated viruses, retroviruses, and lentiviruses. 
However, some hurdles exist that must be overcome before 
this technology will become practical. The first hurdle is 
the optimization of  ex vivo transfection; the second hurdle 
relates to the durability of  the desired gene expression 
because, in most instances, it has been reported that 
expression decreases with time. The efficacy of  gene therapy 
using MSCs will depend on the efficiency with which the 
reagents are incorporated into MSCs and the selection of  
specific targets.
Potential mechanisms of mesenchymal 
stem cell therapy
It was once believed that MSCs repair damaged tissues by 
robustly replacing the damaged cells. However, researchers 
have shown that in response to injury, MSCs secrete large 
quantities of  bioactive molecules; this constitutes the 
most biologically significant role of  MSCs under injury 
conditions.[58] We now know that the paracrine effect of  
MSCs and cell replacement by MSC-derived cells are both 
important. Understanding this intricate activity as well as 
the properties of  MSCs in vivo is central to harnessing their 
clinical potential [Figure 2].[59] 
The secretion of  bioactive molecules can be divided into 
six main categories: immunomodulation, anti-apoptosis, 
angiogenesis, support of  the growth and differentiation 
of  local stem and progenitor cells, anti-scarring and 
chemoattraction.[59] The number of  molecules known to 
mediate the paracrine action of  MSCs increases every day. 
The immunomodulatory effects of  MSCs consist of  the 
inhibition of  immune cell proliferation, the suppression 
of  immunoglobulin production, the inhibition of  dentric 
cell maturation and the stimulation of  regulatory T-cell 
proliferation. MSCs also limit apoptosis and stimulate local 
angiogenesis through the secretion of  extracellular matrix 
molecules. A group of  at least 15 chemokines produced by 
MSCs can elicit leukocyte migration to the injured area.[56] 
Clinical-grade cell manufacture
During clinical applications of  MSCs, the culture conditions 
must be tested and quality controls must be adapted. The 
release criteria of  the cell batch must be strict and must take 
into account the effectiveness of  the cellular product and the 
safety of  the patient. Currently, the MSCs of  many clinical 
research protocols are being generated in hematopoietic 
cell transplantation (HCT) processing laboratories or 
similar facilities. Other protocols employ current Good 
Manufacturing Practice (cGMP) standards, in which the 
cells are manufactured under the highest standards of  
sterility, quality control and documentation. A number 
of  factors in the cell manufacturing process influence the 
nature and function of  the MSCs. 
Although the ISCT has established the definition of  
MSCs,[8,9] a major challenge in establishing release criteria 
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is the lack of  an accepted functional assay. However, given 
the wide range of  the potential clinical effects of  MSCs, 
any such assays will need to be specific to the particular 
indication or clinical trial. There may also be significant 
differences among MSC products from different tissue 
sources. Researchers have compared adipose-derived MSCs 
to MSCs from bone marrow,[60] and the source of  MSCs 
may influence the ability of  the cells to differentiate. Cell-
manufacturing protocols must therefore take into account 
the variability in the characteristics of  the MSCs. To 
mitigate the malignant transformation of  human MSCs, the 
MSCs to be used for clinical treatment must have undergone 
fewer than 25-30 cell doublings.[61] The strategy to make 
the MSC product available quickly is to rapidly grow the 
MSCs in bioreactors. 
Future perspective 
Although perhaps several thousand patients have been 
treated with MSCs to date, no infusional toxicity or 
immediate adverse outcomes have been reported, suggesting 
MSC infusion to be safe. However, MSC therapies have 
potential risks to patients. The collection of  data on patients 
treated with MSCs and the evaluation of  long-term patient 
outcomes can provide an excellent infrastructure that can 
avoid publication bias. A registry specific for novel cellular 
therapies has already been established in the European 
Group for Blood and Marrow Transplantation (EBMT).[62] 
Although many studies have demonstrated the safety and 
effectiveness of  MSC treatment for various diseases, there 
are still many questions to be answered. The first is to 
confirm the therapeutic efficacy of  transplanted MSCs. 
The second is to deeply understand the mechanisms of  
engraftment, homing and in vivo differentiation. The third 
is the availability of  validated in vitro methods for the 
large-scale production of  MSCs for clinical applications. 
The final question is the need for novel engineered devices 
for the tissue-specific delivery of  MSCs. As these areas 
are addressed, the clinical significance of  MSCs will be 
tremendously promoted. 
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